Cancer vaccine MUC-1 - GSK/University of Pittsburgh
Alternative Names: MUC-1 peptide vaccine - GSK/University of PittsburghLatest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline; University of Pittsburgh
- Developer GSK; University of Pittsburgh
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Pancreatic cancer
Most Recent Events
- 26 Jan 2007 No development reported - Phase-I for Cancer in USA (Injection)
- 26 Jan 2007 No development reported - Phase-I for Pancreatic cancer in USA (Injection)
- 30 Jul 2002 This vaccine is still in active development